Beam Therapeutics Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Beam Therapeutics Inc. (BEAM) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-08-04
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-06-30 was $0.00.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-03-31 was $0.00.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $0.00.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was -$399.00K.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was -$399.00K.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $0.00.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $0.00.
- Beam Therapeutics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was $0.00.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | -$399.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | -$399.00K derived: sum of 3 quarters · filed 2026-05-07 | -$399.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$399.00K derived: sum of 2 quarters · filed 2026-02-24 | -$399.00K derived: sum of 3 quarters · filed 2026-08-04 | -$399.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | -$399.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$399.00K derived: sum of 2 quarters · filed 2026-08-04 | -$399.00K 10-Q · filed 2025-11-04 | -$399.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |